Showing Results for
- Academic Journals (82)
Search Results
- 82
Academic Journals
- 82
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor(s): Jean Peccoud 1, J Christopher Anderson 2, Deepak Chandran 3, Douglas Densmore 4, Michal Galdzicki 5, Matthew W Lux 1, Cesar A Rodriguez 6, Guy-Bart Stan 7, Herbert M Sauro 3 Author Affiliations: (1)...
- 2From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor(s): H Craig Mak 1 Author Affiliations: (1) H. Craig Mak is Associate Editor, Nature Biotechnology, Why have computer scientists long endeavored to create software capable of accomplishing tasks humans can...
- 3From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor(s): H Craig Mak 1 Author Affiliations: (1) H. Craig Mak is Associate Editor, Nature Biotechnology, Imagine an experiment generating a billion data points every day, the equivalent of running millions of...
- 4From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor Affiliations: The Ontario Genomics Institute (Toronto) has announced the appointment of Mark J. Poznansky (below, right) as president and CEO, replacing Christian Burks. Poznansky has served on the OGI board of...
- 5From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor Affiliations: Nature Biotechnology replies: Kemmer et al.1 have now lodged the sequences of the constructs used in their paper with GenBank Nature Biotechnology and other Nature research journals currently...
- 6From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor Affiliations: Aptamer-based proteomics arrays Progress in the use of high-throughput proteomic analysis for biomarker discovery and diagnostics has been stymied by the challenge of quantifying tens of...
- 7From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor(s): H Craig Mak 1 Author Affiliations: (1) H. Craig Mak is Associate Editor, Nature Biotechnology, Businesses and broad segments of society have recently embraced decentralized mechanisms of information...
- 8From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor(s): H Craig Mak 1 Author Affiliations: (1) H. Craig Mak is Associate Editor, Nature Biotechnology, In the course of compiling this survey, several investigators remarked that it tends to be easier for...
- 9From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor(s): James T Robinson 1 , Helga Thorvaldsdóttir 1 , Wendy Winckler 1 , Mitchell Guttman 1 2 , Eric S Lander 1 2 3 , Gad Getz 1 , Jill P Mesirov 1 Author Affiliations: (1) Broad Institute of Massachusetts...
- 10From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedAuthor(s): H Craig Mak 1 Author Affiliations: (1) H. Craig Mak is Associate Editor, Nature Biotechnology, Electronic medical records are becoming a reality, promising lower health-care costs, improved patient...
- 11From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedTake it as a metaphor for the bioplastics industry as a whole, or as another example of a fledgling industry stuttering toward success. In October of last year, Cambridge, Massachusetts, biotech Metabolix produced a new...
- 12From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedA $2.2 billion deal in October between Macrogenics and Boehringer Ingelheim, followed the next month by another eye-catching $1.7-billion research collaboration between f-star and the German pharma are the latest in a...
- 13From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedThe European regulatory authorities continue to make strides forward with biosimilars. Indeed, the latest advice from the European Medicines Agency (EMA) to those seeking to produce biosimilar monoclonal antibodies...
- 14From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedEuropean regulators laid out the rules for copying biotech's blockbuster monoclonal antibody (mAb) therapies, paving the way for biosimilars developers to access the $36.4 billion market. The draft guidelines, published...
- 15From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedScreening for safe harbor sites in the genome may improve the safety of gene therapy. Author(s): David A Williams 1 , Adrian J Thrasher 2 Author Affiliations: (1) David A. Williams is at Children's Hospital...
- 16From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedSteve Self, development director at e-Therapeutics (Newcastle upon Tyne, UK), has agreed to become an executive director on the company's board. He previously served as group R&D director at Merck Generics and worked...
- 17From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedIn November, Roche revealed sweeping cuts in its workforce as part of its so-called Operational Excellence Program to reduce costs. Over 4,800 people, 6% of its workforce, will lose their jobs and another 700 will be...
- 18From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedThe latest edition of CompStudy (http://www.compstudy.com), a compensation study released by J. Robert Scott and Ernst & Young, revealed that total target cash compensation in 2010 at private life sciences firms was up...
- 19From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedRealizing the therapeutic potential of human induced piuripotent stem (iPS) cells will require robust, precise and safe strategies for genetic modification, as cell therapies that rely on randomly integrated transgenes...
- 20From: Nature Biotechnology. (Vol. 29, Issue 1) Peer-ReviewedFood from cloned animals is under fire in Europe with the European Commission (EC) calling in October for a temporary commercial suspension. John Dalli, European commissioner for health and consumer policy, describes...